Widespread alteration of protein autoinhibition in human cancers

Autoinhibition is a prevalent allosteric regulatory mechanism in signaling proteins as it prevents spurious pathway activation and primes for signal propagation only under appropriate inputs. Altered functioning of inhibitory allosteric switches underlies the tumorigenic potential of numerous cancer drivers. However, whether protein autoinhibition is altered generically in cancer cells remains elusive. Here, we reveal that cancer-associated missense mutations and fusion breakpoints are found with significant enrichment within inhibitory allosteric switches across all cancer types, which in the case of the fusion breakpoints is specific to cancer and not present in other diseases. Recurrently disrupted or mutated allosteric switches identify established and new cancer drivers. Cancer-specific mutations in allosteric switches are associated with distinct changes in signaling, and suggest molecular mechanisms for altered protein regulation, which in the case of ASK1, DAPK2 and EIF4G1 were supported by biophysical simulations. Our results demonstrate that autoinhibition-modulating genetic alterations are positively selected for by cancer cells, and that their study provides valuable insights into molecular mechanisms of cancer misregulation.

• Publication year

  2018

• Venue

  bioRxiv

• Publication date

  2018-10-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/450296
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Comprehensive Characterization of Cancer Driver Genes and Mutations

  2018cited by this paper
• Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs

  2018cited by this paper
• Structural basis of autoregulatory scaffolding by apoptosis signal-regulating kinase 1

  2017cited by this paper
• Βeta-catenin N-terminal domain: An enigmatic region prone to cancer causing mutations.

  2017cited by this paper
• Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1

  2017cited by this paper
• Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer.

  2017cited by this paper
• Structural Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40

  2017cited by this paper
• Implementing Genome-Driven Oncology.

  2017cited by this paper
• Evaluating the evaluation of cancer driver genes

  2016cited by this paper
• Systems-wide Identification of cis-Regulatory Elements in Proteins.

  2016cited by this paper
• KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis

  2016cited by this paper
• Modulating Dickkopf-1: A Strategy to Monitor or Treat Cancer?

  2016cited by this paper
• Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

  2016cited by this paper
• ChimerDB 3.0: an enhanced database for fusion genes from cancer transcriptome and literature data mining

  2016cited by this paper
• PathwAX: a web server for network crosstalk based pathway annotation

  2016cited by this paper
• Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

  2016cited by this paper
• Toward a Shared Vision for Cancer Genomic Data.

  2016cited by this paper
• GTRD: a database of transcription factor binding sites identified by ChIP-seq experiments

  2016cited by this paper
• P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer.

  2016cited by this paper
• Germline NLRP1 Mutations Cause Skin Inflammatory and Cancer Susceptibility Syndromes via Inflammasome Activation.

  2016cited by this paper
• Nuclear import mechanism of neurofibromin for localization on the spindle and function in chromosome congression

  2016cited by this paper
• Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer

  2016cited by this paper
• Discovering and understanding oncogenic gene fusions through data intensive computational approaches

  2016cited by this paper
• Systemic Reprogramming of Translation Efficiencies on Oxygen Stimulus.

  2016cited by this paper
• InterPro in 2017—beyond protein family and domain annotations

  2016cited by this paper
• Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.

  2016cited by this paper
• Terminal regions of β-catenin are critical for regulating its adhesion and transcription functions.

  2016cited by this paper
• DAPK2 regulates oxidative stress in cancer cells by preserving mitochondrial function

  2015cited by this paper
• Targeting the translation machinery in cancer

  2015cited by this paper
• The Pfam protein families database: towards a more sustainable future

  2015cited by this paper
• DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis

  2015cited by this paper
• The BRAF kinase domain promotes the development of gliomas in vivo

  2015cited by this paper
• Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival

  2015cited by this paper
• FusionCancer: a database of cancer fusion genes derived from RNA-seq data

  2015cited by this paper
• ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB.

  2015cited by this paper
• Ensembl 2016

  2015cited by this paper
• Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site

  2015cited by this paper
• Driver and passenger mutations in cancer.

  2015cited by this paper
• Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I

  2015cited by this paper
• Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

  2015cited by this paper
• The emerging complexity of gene fusions in cancer

  2015cited by this paper
• Resource Kinome-wide Decoding of Network-Attacking Mutations Rewiring Cancer Signaling Graphical Abstract Highlights

  2015cited by this paper
• Recurrent PTPRB and PLCG1 mutations in angiosarcoma

  2014cited by this paper
• COSMIC: exploring the world's knowledge of somatic mutations in human cancer

  2014cited by this paper
• GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation

  2014cited by this paper
• Mutation of Vav1 adaptor region reveals a new oncogenic activation

  2014cited by this paper
• The landscape and therapeutic relevance of cancer-associated transcript fusions

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Mutational heterogeneity in cancer and the search for new cancer genes

  2014cited by this paper
• e-Driver: a novel method to identify protein regions driving cancer

  2014cited by this paper
• Situational Awareness: Regulation of the Myb Transcription Factor in Differentiation, the Cell Cycle and Oncogenesis

  2014cited by this paper
• B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)

  2014cited by this paper
• The landscape of kinase fusions in cancer

  2014cited by this paper
• Targeting β-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours

  2014cited by this paper
• Global analysis of protein structural changes in complex proteomes

  2014cited by this paper
• NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors

  2013cited by this paper
• Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity

  2013cited by this paper
• GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• IntOGen-mutations identifies cancer drivers across tumor types

  2013cited by this paper
• Cancer Genome Landscapes

  2013cited by this paper
• Structure and intrinsic disorder in protein autoinhibition.

  2013cited by this paper
• OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes

  2013cited by this paper
• Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies

  2012cited by this paper
• cGMP-dependent protein kinase I promotes cell apoptosis through hyperactivation of death-associated protein kinase 2.

  2012cited by this paper
• Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers

  2012cited by this paper
• Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.

  2012cited by this paper
• Pannexin 1, an ATP Release Channel, Is Activated by Caspase Cleavage of Its Pore-associated C-terminal Autoinhibitory Region*♦

  2012cited by this paper
• Cell cycle control of Wnt/β‐catenin signalling by conductin/axin2 through CDC20

  2012cited by this paper
• Functional impact bias reveals cancer drivers

  2012cited by this paper
• DNA damage and eIF4G1 in breast cancer cells reprogram translation for survival and DNA repair mRNAs

  2012cited by this paper
• Frequent somatic MAP3K5 and MAP3K9 mutations in metastatic melanoma identified by exome sequencing

  2011cited by this paper
• Development of an Effective Therapy for Chronic Myelogenous Leukemia

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse

  2011cited by this paper
• Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain.

  2010cited by this paper
• The cancer genome

  2009cited by this paper
• Modeling chromosomal translocations using conditional alleles to recapitulate initiating events in human leukemias.

  2008cited by this paper
• Crystal structure of a full-length beta-catenin.

  2008cited by this paper
• Cancer Proliferation Gene Discovery Through Functional Genomics

  2008cited by this paper
• Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma

  2008cited by this paper
• Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

  2007cited by this paper
• A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer.

  2007cited by this paper
• Identification and characterization of Asef2, a guanine–nucleotide exchange factor specific for Rac1 and Cdc42

  2007cited by this paper
• Structural basis for autoinhibition of Notch

  2007cited by this paper
• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  2007cited by this paper
• Thermodynamics of beta-catenin-ligand interactions: the roles of the N- and C-terminal tails in modulating binding affinity.

  2006cited by this paper
• Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent

  2006cited by this paper
• Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent.

  2006cited by this paper
• From Kinases to Cancer: Leakiness, Loss of Autoinhibition and Leukemia

  2006cited by this paper
• Autoinhibited proteins as promising drug targets

  2004cited by this paper
• Neurofibromin is actively transported to the nucleus

  2004cited by this paper
• A census of human cancer genes

  2004cited by this paper
• Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region

  2003cited by this paper
• Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

  2003cited by this paper
• Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

  2003cited by this paper
• Structural basis for the autoinhibition of c-Abl tyrosine kinase.

  2003cited by this paper
• Autoinhibition Control

  2003cited by this paper
• Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

  2003cited by this paper
• Regulation of tumor suppressors by nuclear-cytoplasmic shuttling.

  2003cited by this paper

• No citing papers are available for this paper.